Immunoglobulin light-chain amyloidosis: Growing recognition, new approaches to therapy, active clinical trials

Oncology

Volumn 26, Issue 2, 2012, Pages 1-14

  Gertz, Morie A ^a   Dispenzieri, Angela ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID; BENDAMUSTINE; BORTEZOMIB; CONGO RED; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; MLN 9708; PLASMA PROTEIN; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; THALIDOMIDE; TROPONIN T; UNCLASSIFIED DRUG;

ALBUMINURIA; AMYLOIDOSIS; CARDIOMYOPATHY; CONSTIPATION; CYTOPENIA; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG MEGADOSE; DYSPNEA; ELECTROCARDIOGRAPHY; FATIGUE; HEART AMYLOIDOSIS; HEART CATHETERIZATION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HUMAN; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; LEG EDEMA; LYMPHOMA; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; OVERALL SURVIVAL; PERIORBITAL PURPURA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEIN ELECTROPHORESIS; PROTEIN URINE LEVEL; PROTEINURIA; PURPURA; REVIEW; SENSORIMOTOR NEUROPATHY; SINUS HISTIOCYTOSIS; SOMNOLENCE; STAINING; STEM CELL TRANSPLANTATION; SURVIVAL; TONGUE; TONGUE ENLARGEMENT; UNSPECIFIED SIDE EFFECT; URINE IMMUNOFIXATION;

EID: 84857067479     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Baden EM, Sikkink LA, Ramirez-Alvarado M. Light chain amyloidosiscurrent findings and future prospects. Curr Protein Pept Sci. 2009;10:500-8.
2. Bhat A, Selmi C, Naguwa SM, et al. Currents concepts on the immunopathology of amyloidosis. Clin Rev Allergy Immunol. 2010;38:97-106.
3. Halloush RA, Lavrovskaya E, Mody DR, et al. Diagnosis and typing of systemic amyloidosis: the role of abdominal fat pad fine needle aspiration biopsy. Cytojournal. 2010;6:24.
4. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924-33.
5. Bellavia D, Abraham RS, Pellikka PA, et al. Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (AL). J Am Soc Echocardiogr. 2011;24:444-54.
6. Mesquita M, Fosso C, Bakoto Sol E, et al. Renal biopsy findings in Belgium: a retrospective single center analysis. Acta Clin Belg. 2011;66:104-9.
7. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55:1517-22.
8. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma. 2005;6:208-19.
9. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108:2520-30.
10. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc. 2010;85:225-30.
11. Angiero F, Seramondi R, Magistro S, et al. Amyloid deposition in the tongue: clinical and histopathological profile. Anticancer Res. 2010;30:3009-14.
12. Lee HJ, Chang SE, Lee MW, et al. Systemic amyloidosis associated with multiple myeloma presenting as periorbital purpura. J Dermatol. 2008;35:371-2.
13. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23:215-24.
14. Petruzziello F, Zeppa P, Catalano L, et al. Amyloid in bone marrow smears of patients affected by multiple myeloma. Ann Hematol. 2010;89:469-74.
15. Ohno F, Numata Y, Yamano T, et al. Gastroscopic biopsy of the stomach for the diagnosis of amyloidosis. Gastroenterol Jpn. 1982;17:415-21.
16. Fernandez-Flores A. Comparative study of Congo red fluorescence and immunohistochemistry in cutaneous amyloidosis. Rom J Morphol Embryol. 2010;51:683-6.
17. Foli A, Palladini G, Caporali R, et al. The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid. 2011;18(Suppl 1):75-7.
18. Tam M, Seldin DC, Forbes BM, et al. Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature review. Amyloid. 2009;16:103-7.
19. Shidham VB, Hunt B, Jardeh SS, et al. Performing and processing FNA of anterior fat pad for amyloid. J Vis Exp. 2010; 44: pii 1747.
20. Siragusa S, Morice W, Gertz MA, et al. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol. 2011;90:101-6.
21. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166:1805-13.
22. Liu D, Niemann M, Hu K, et al. Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis. Am J Cardiol. 2011;108:591-8.
23. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751-7.
24. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104:1881-7.
25. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116:3426-30.
26. Gertz M, Lacy M, Dispenzieri A, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma. 2008;49:36-41.
27. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006;107:3378-83.
28. Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011;46:970-5.
29. Kumar S, Dispenzieri A, Lacy MQ, et al. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc. 2008;83:297-303.
30. Palladini G, Dispenzieri A, Gertz MA, et al. Validation of the criteria of response to treatment in AL amyloidosis. ASH Annual Meeting Abstracts 2010;116:1364.
31. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86:12-8.
32. Wall JS, Kennel SJ, Stuckey AC, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010;116:2241-4.
33. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468:93-7.
34. Hovey BM, Ward JE, Soo Hoo P, et al. Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther. 2011;18:1150-6.
35. Jones NF, Hilton PJ, Tighe JR Hobbs JR. Treatment of "primary" renal amyloidosis with melphalan. Lancet. 1972;2:616-9.
36. Dhodapkar MV, Hussein MA, Rasmussen E, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood. 2004;104:3520-6.
37. Comenzo RL. Who knows how to treat systemic light chain amyloidosis? Oncology (Williston Park). 2011;25:626, 28-9, 32-3.
38. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063-73.
39. Gertz MA, Ansell SM, Dingli D, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc. 2008;83:1131-8.
40. Madan S, Kumar S, Lacy MQ, et al. Pre-stem cell transplant induction therapy does not affect post-transplant survival in light chain (AL) amyloidosis. ASH Annual Meeting Abstracts. 2010;116:370.
41. Chow LQ, Bahlis N, Russell J, et al. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplant. 2005;36:591-6.
42. Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51:2181-7.
43. Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118:4346-52.
44. Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma. 2003;3:241-6.
45. Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005;105:2949-51.
46. Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109:457-64.
47. Specter R, Sanchorawala V, Seldin DC, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant. 2011;26:881-6.
48. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109:492-6.
49. Sanchorawala V, Finn KT, Fennessey S, et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood. 2010;116:1990-1.
50. Palladini G, Russo P, Foli A, et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol. 2012;91:89-92.
51. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010;116:4777-82.
52. Kumar S, Hayman SR, Buadi F. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis [abstract 3853]. Blood. 2009;114:1482.
53. Dispenzieri A, Gertz MA Hayman SR. A pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients [abstract 3854]. Blood. 2009;114:1482-3.
54. Wechalekar AD, Lachmann HJ, Offer M, et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93:295-8.
55. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92:1351-8.
56. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118:865-73.
57. Landau H, Hassoun H, Bello C, et al. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid. 2011;18(Suppl 1):130-1.
58. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28:1031-7.
59. Sanchorawala V, Quillen K, Sloan JM, et al. Bortezomib and high dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica. 2011;96:1890-2.
60. Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol. 2011;90:201-6.
61. Kumar SK, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol. 2011;86:251-5.
62. Herrera GA, Teng J, Turbat-Herrera EA. Renal amyloidosis: current views on pathogenesis and impact on diagnosis. Contrib Nephrol. 2011;169:232-46.
63. Sikkink LA Ramirez-Alvarado M. Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture. Cell Death Dis. 2010;1:e98.